# Refining a mouse model of progressive supranuclear palsy through inoculation of human post-mortem brain-derived tau

**Authors:** S. H. Qamar, A. Mao, R. Ferry, S. Thapa, P. Singh, M. C. Tartaglia, M. S. Pollanen, A. E. Lang, H. Tanaka, I. Martinez-Valbuena, N. P. Visanji

PMC · DOI: 10.1186/s13104-025-07599-0 · BMC Research Notes · 2026-01-06

## TL;DR

Researchers are working to create a better mouse model for Progressive Supranuclear Palsy by using human brain-derived tau.

## Contribution

The study identifies a limitation in using 2% sarkosyl-insoluble tau for modeling Progressive Supranuclear Palsy in mice.

## Key findings

- Inoculation of 2% sarkosyl-insoluble tau into mice reproduces key features of PSP pathology.
- The limited yield of 2% sarkosyl-insoluble tau hinders scalability and reproducibility of the model.
- Alternative methods for generating tau seeds are needed for a robust PSP model.

## Abstract

A major obstacle to developing effective therapies for Progressive Supranuclear Palsy (PSP), a uniformly fatal 4R tauopathy, is the absence of an animal model that faithfully reproduces the anatomical, cytopathological, and spatiotemporal progression of disease. Inoculation-based models, using human postmortem brain material bearing disease-specific proteopathic tau seeds, hold great translational potential for modeling tauopathies. Here we conducted key studies towards the development of an inoculation-based PSP model, using human postmortem brain to target three subcortical nuclei impacted in early disease.

We evaluated the impact of five different PSP brain extracts on the extent and distribution of tau pathology following inoculation into 6hTau transgenic mice expressing all six isoforms of human tau. Our findings demonstrate that 2% sarkosyl-insoluble tau successfully recapitulates core cytopathological features of PSP when introduced into disease-relevant nuclei. However, we also identify a major limitation in the restricted yield of 2% sarkosyl-insoluble tau, which significantly impedes the scalability and reproducibility of this approach. We conclude that further progress will likely require alternative strategies to generate a stable and scalable source of tau proteopathic seeds, to support a robust and reproducible inoculation-based mouse model of PSP.

The online version contains supplementary material available at 10.1186/s13104-025-07599-0.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau)
- **Chemicals:** sarkosyl (PubChem CID 7348)
- **Diseases:** Progressive Supranuclear Palsy (MONDO:0019037), PSP (MONDO:0010997)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}
- **Diseases:** 4R tauopathy (MESH:D024801), PSP (MESH:D013494)
- **Chemicals:** sarkosyl (MESH:C025231), 6hTau (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12870344/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12870344/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12870344/full.md

---
Source: https://tomesphere.com/paper/PMC12870344